FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040872477> ?p ?o ?g. }

• W2040872477 endingPage "1692" @default.
• W2040872477 startingPage "1687" @default.
• W2040872477 abstract "Abstract BACKGROUND Arsenic trioxide induces growth inhibition and apoptosis in human melanoma cell lines. Therefore, a Phase II trial was conducted to evaluate the efficacy and toxicity of single‐agent arsenic trioxide in patients with Stage IV melanoma. METHODS Twenty patients, 10 with metastatic melanoma of cutaneous origin and 10 with metastatic melanoma of choroidal origin, received arsenic trioxide 0.25 mg/kg/day for 5 days, followed by a maintenance dose of 0.35 mg/kg/day twice a week. All patients with melanoma of cutaneous origin and four patients with melanoma of choroidal origin had received prior therapy. RESULTS Single‐agent arsenic trioxide did not induce clinical response in this patient population. Eight patients (five with melanoma of cutaneous origin, and three with melanoma of choroidal origin) had disease stabilization for at least six weeks. The median overall survival duration for patients with melanoma of cutaneous origin was 7.9 months, and that of patients with melanoma of choroidal origin has not been reached at a median follow‐up duration of 11.8 months. Grade 3 toxicity included neutropenia, fatigue, abdominal pain, and arthralgia. Grade 4 toxicity did not occur. CONCLUSIONS Single‐agent arsenic trioxide was generally well tolerated; however, no tumor regression was observed in this patient population. Future clinical trials should evaluate arsenic trioxide in combination with other anticancer drugs that may improve its clinical activity in melanoma. Cancer 2005. © 2005 American Cancer Society." @default.
• W2040872477 created "2016-06-24" @default.
• W2040872477 creator A5011465880 @default.
• W2040872477 creator A5015498468 @default.
• W2040872477 creator A5060563693 @default.
• W2040872477 creator A5078841756 @default.
• W2040872477 creator A5086563151 @default.
• W2040872477 date "2005-10-03" @default.
• W2040872477 modified "2023-10-18" @default.
• W2040872477 title "A phase II trial of arsenic trioxide in patients with metastatic melanoma" @default.
• W2040872477 cites W134636856 @default.
• W2040872477 cites W1969062733 @default.
• W2040872477 cites W1978023445 @default.
• W2040872477 cites W1995727471 @default.
• W2040872477 cites W1997919830 @default.
• W2040872477 cites W1998477498 @default.
• W2040872477 cites W2006985176 @default.
• W2040872477 cites W2029409133 @default.
• W2040872477 cites W2030095430 @default.
• W2040872477 cites W2049457454 @default.
• W2040872477 cites W2067465277 @default.
• W2040872477 cites W2070394850 @default.
• W2040872477 cites W2082267009 @default.
• W2040872477 cites W2086412586 @default.
• W2040872477 cites W2088104197 @default.
• W2040872477 cites W2131365547 @default.
• W2040872477 cites W2139248078 @default.
• W2040872477 cites W2139771875 @default.
• W2040872477 cites W2154914116 @default.
• W2040872477 cites W2165636771 @default.
• W2040872477 cites W2166901281 @default.
• W2040872477 cites W2167530806 @default.
• W2040872477 doi "https://doi.org/10.1002/cncr.21386" @default.
• W2040872477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16130126" @default.
• W2040872477 hasPublicationYear "2005" @default.
• W2040872477 type Work @default.
• W2040872477 sameAs 2040872477 @default.
• W2040872477 citedByCount "59" @default.
• W2040872477 countsByYear W20408724772012 @default.
• W2040872477 countsByYear W20408724772013 @default.
• W2040872477 countsByYear W20408724772014 @default.
• W2040872477 countsByYear W20408724772015 @default.
• W2040872477 countsByYear W20408724772016 @default.
• W2040872477 countsByYear W20408724772018 @default.
• W2040872477 countsByYear W20408724772020 @default.
• W2040872477 countsByYear W20408724772021 @default.
• W2040872477 countsByYear W20408724772023 @default.
• W2040872477 crossrefType "journal-article" @default.
• W2040872477 hasAuthorship W2040872477A5011465880 @default.
• W2040872477 hasAuthorship W2040872477A5015498468 @default.
• W2040872477 hasAuthorship W2040872477A5060563693 @default.
• W2040872477 hasAuthorship W2040872477A5078841756 @default.
• W2040872477 hasAuthorship W2040872477A5086563151 @default.
• W2040872477 hasBestOaLocation W20408724771 @default.
• W2040872477 hasConcept C126322002 @default.
• W2040872477 hasConcept C141071460 @default.
• W2040872477 hasConcept C143998085 @default.
• W2040872477 hasConcept C16005928 @default.
• W2040872477 hasConcept C191897082 @default.
• W2040872477 hasConcept C192562407 @default.
• W2040872477 hasConcept C2777063308 @default.
• W2040872477 hasConcept C2777658100 @default.
• W2040872477 hasConcept C2780386689 @default.
• W2040872477 hasConcept C2908647359 @default.
• W2040872477 hasConcept C29730261 @default.
• W2040872477 hasConcept C31760486 @default.
• W2040872477 hasConcept C502230775 @default.
• W2040872477 hasConcept C502942594 @default.
• W2040872477 hasConcept C71924100 @default.
• W2040872477 hasConcept C90924648 @default.
• W2040872477 hasConcept C99454951 @default.
• W2040872477 hasConceptScore W2040872477C126322002 @default.
• W2040872477 hasConceptScore W2040872477C141071460 @default.
• W2040872477 hasConceptScore W2040872477C143998085 @default.
• W2040872477 hasConceptScore W2040872477C16005928 @default.
• W2040872477 hasConceptScore W2040872477C191897082 @default.
• W2040872477 hasConceptScore W2040872477C192562407 @default.
• W2040872477 hasConceptScore W2040872477C2777063308 @default.
• W2040872477 hasConceptScore W2040872477C2777658100 @default.
• W2040872477 hasConceptScore W2040872477C2780386689 @default.
• W2040872477 hasConceptScore W2040872477C2908647359 @default.
• W2040872477 hasConceptScore W2040872477C29730261 @default.
• W2040872477 hasConceptScore W2040872477C31760486 @default.
• W2040872477 hasConceptScore W2040872477C502230775 @default.
• W2040872477 hasConceptScore W2040872477C502942594 @default.
• W2040872477 hasConceptScore W2040872477C71924100 @default.
• W2040872477 hasConceptScore W2040872477C90924648 @default.
• W2040872477 hasConceptScore W2040872477C99454951 @default.
• W2040872477 hasIssue "8" @default.
• W2040872477 hasLocation W20408724771 @default.
• W2040872477 hasLocation W20408724772 @default.
• W2040872477 hasOpenAccess W2040872477 @default.
• W2040872477 hasPrimaryLocation W20408724771 @default.
• W2040872477 hasRelatedWork W1992304316 @default.
• W2040872477 hasRelatedWork W2287670947 @default.
• W2040872477 hasRelatedWork W2320262955 @default.
• W2040872477 hasRelatedWork W2357909182 @default.
• W2040872477 hasRelatedWork W2358367877 @default.

• next